Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | The potential of gene-edited effector cell therapy

Maksim Mamonkin • 20 Aug 2020
EBMT 2020
General CAR-T

Maksim Mamonkin, PhD, Baylor College of Medicine, Houston, TX, discusses gene-edited effector cell therapy, and its potential to improve the outcomes of T-cell therapies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Maksim Mamonkin

2:05
Using engineered T-cells to suppress acute GvHD and leukemia relapse after alloSCT
Maksim Mamonkin • 10 Feb 2023
1:51
CAR-T cell therapy for T-cell malignancies: challenges to address and future outlooks
Maksim Mamonkin • 10 Feb 2023
2:14
Exploring the potential role of CD7-targeting CAR-T cells for the treatment of T-ALL
Maksim Mamonkin • 10 Feb 2023
2:59
CD5 and CD7 directed CAR T-cells for pediatric T-cell malignancies
Maksim Mamonkin • 1 Sep 2020

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals